Online inquiry

IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15756MR)

This product GTTS-WQ15756MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CA9 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001216.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15756MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12929MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ6356MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ11788MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-3222
GTTS-WQ980MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ7056MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ4264MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ3899MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ8509MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Hu3F8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW